AcelRx (ACRX) shares slumped in trading today after disappointing earnings results. The company reported $613K in revenue vs. $1.51M consensus estimate. While this was less than half of what was expected, it was not a huge surprise since the company missed revenue estimates by comparable margins over the previous five earnings releases. However, there was good news as well, as the company reported its product launch of Dsuvia was going either as planned or better than expected. The company even raised its expectations for contract acquisitions. Here’s a recap.
